Vor Biopharma Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Vor Biopharma Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$371.64M	-$121.19M	-$93.42M	-$69.02M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$695.98M	-$116.91M	-$92.09M	-$68.90M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-70.50	$-1.70	$-2.33	$-2.10
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-70.50	$-1.70	$-2.33	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$396.49M	$81.95M	$57.71M	$119.80M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$464.13M	$142.89M	$299.37M	$242.59M
Everything the company owes — debt, unpaid bills, and other obligations.	$628.44M	$46.23M	$48.76M	$26.33M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$164.31M	$96.66M	$250.61M	$216.26M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$142.71M	-$99.66M	-$85.14M	-$69.14M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$941000	$229000	$8.46M	$3.89M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$143.65M	-$99.89M	-$93.61M	-$73.04M